US Stock MarketDetailed Quotes
SPRC SciSparc
- 0.6430
- -0.0866-11.87%
Close Jul 19 16:00 ET
- 0.6389
- -0.0041-0.64%
Pre 07:18 ET
2.09MMarket Cap-44P/E (TTM)
0.6925High0.6380Low805.08KVolume0.6925Open0.7296Pre Close527.94KTurnover24.79%Turnover RatioLossP/E (Static)3.25MShares15.857452wk High0.27P/B2.09MFloat Cap0.638052wk Low--Dividend TTM3.25MShs Float221.0000Historical High--Div YieldTTM7.47%Amplitude0.0026Historical Low0.6550Avg Price1Lot Size
SciSparc Stock Forum
Sign in to post a comment
$SciSparc(SPRC.US$ Scisparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 Million
2
$SciSparc(SPRC.US$
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
SciSparc (Nasdaq: SPRC) has signed a non-binding letter of intent (LOI) for the exclusive global out-licensing of its SCI-160 pain treatment program. The deal, valued at approximately $6 million, includes:
1. $3 million in ordinary shares and pre-funded warrants of the undisclosed biotechnology company
2. Potential additional payments and execution...
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
SciSparc (Nasdaq: SPRC) has signed a non-binding letter of intent (LOI) for the exclusive global out-licensing of its SCI-160 pain treatment program. The deal, valued at approximately $6 million, includes:
1. $3 million in ordinary shares and pre-funded warrants of the undisclosed biotechnology company
2. Potential additional payments and execution...
$SciSparc(SPRC.US$ absolute piece of shit
3
3
$SciSparc(SPRC.US$ .9 is support
3
$SciSparc(SPRC.US$ I didn’t sell cause i missed both spikes because I’m at work. I am in at 1.15. Any chance this will make it back to the area?
2
1
$SciSparc(SPRC.US$ Ride this Bull!
2
$SciSparc(SPRC.US$ If you buy in the premarket, sell in the premarket, don't take the risk.👀
2
$SciSparc(SPRC.US$ i will be super happy if it hits 2 dollars
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Arrayfunction : I think this industry has huge potential; but friendly reminder to folks to use more caution with companies relying on *only* cannabinoids or other psychedelic drug candidates!
Before making a major investment, I highly recommend someone read up on the extra challenges those face in development compared to your standard small-biotech in the country they are working out of. My personal rule of thumb is to double the amount of time you'd except before hitting market.
In the US, trying to do research on anything with or derived from a schedule I classification is an absolute nightmare. Even at the pre-clinical animal level, the red tape explodes exponentially. The overhead as well as time to completion on every project will balloon due to needing to have the DEA oversight on every step, less choice when it comes to supply chains and needing to take on higher interest rates for company debt.
Additional liquidity becomes harder too as a good number of grants can't be used for Schedule I research, investors need to balance the bad press risk, and banks are still largely in agreement not to touch Schedule I projecta or products (e.g. why legal dispensaries are almost always cash-based, no banks will take their deposits)
If you are looking for a short swing gain, you are probably okay thinking about the same as small bio-tech since that is going to be more hypetrain than facts. But dangerous to ignore if you are trying to take a long position
Stock_DriftOP Arrayfunction: I trade and invest. Thank you for taking the time here to explain this position. I appreciate it.
